Sign in Subscribe
health

Every Medicine Has a Second Price Tag

"There ain't no such thing as a free lunch." — Robert A. Heinlein, The Moon Is a Harsh Mistress

Open the cabinet of a family that has been managing asthma and allergies for a few years and look at what has accumulated. A rescue inhaler. A daily controller. An allergy pill. A nasal spray, maybe two. The "PM" sleep aid for the parent. A chewable tablet for the kid. Every one of them arrived for a real reason, prescribed or bought to solve something specific.

And not one of them has ever been looked at as a set, or itemized for what it costs when it runs for years instead of weeks. Because every medicine has a second price tag, the one the box does not print, and the recurring lesson of this inventory is that the price usually rides on a mechanism, not a brand, which is exactly why the label hides it. Here is the cabinet, itemized.

Antihistamines: the hidden variable is anticholinergic burden, not the brand

The allergy aisle quietly splits into two very different drugs. First-generation antihistamines (the old ones, diphenhydramine and chlorpheniramine, the active ingredient in Benadryl and most "PM" sleep products) cross easily into the brain. Second-generation antihistamines (cetirizine, loratadine, fexofenadine) barely do.

That difference matters because of anticholinergic burden (the total load of drugs that block acetylcholine, a key signaling chemical in the brain and body, a load that adds up across completely unrelated medicines). The first-generation antihistamines carry it. In older adults, cumulative use of strong anticholinergic drugs is tied, dose-dependently, to a higher risk of dementia. So the everyday trap is not exotic, it is the nightly diphenhydramine in a "PM" sleep product, the same sedating molecule sold as an allergy pill and again as a sleep aid, taken for years without anyone counting it as the brain-active anticholinergic it is. The practical reframe: for routine allergy control, the second-generation antihistamines do the job without the brain exposure, and reaching reflexively for the old sedating one, for a child or an adult, is the avoidable cost.

Montelukast: the mood-and-sleep cost, and the boxed warning

Montelukast is a leukotriene receptor antagonist (a controller pill that blocks one inflammatory messenger), and it carries the FDA's strongest alert, a boxed warning for neuropsychiatric effects: mood changes, sleep disturbance, agitation, and, rarely, suicidal thoughts.

Read the evidence honestly, because it is genuinely mixed. The most rigorous study in children, a nationwide Swedish register cohort of about 74,000 kids aged 6 to 17, found essentially identical rates against another controller, 2.39 versus 2.41 events per 100 patient-years, and the population-level signal has not been confirmed in several big datasets. But an adult cohort did find more new anxiety and insomnia on the drug, and a real-life pediatric study found that around one in six children had behavioral effects prompting them to stop it, usually within the first two weeks. The reassuring counterpoint is that these effects reliably reverse when the drug is stopped. So the posture is not panic, it is informed vigilance: a reasonable medicine for the right child, started knowing what to watch for, and any new mood, sleep, or behavior change is worth a prompt call to the prescriber rather than a wait-and-see.

Relievers: overuse is a warning light

The rescue inhaler is a short-acting beta-agonist (the fast reliever that opens the airway muscle), and its second price tag is not really a side effect, it is a signal. Leaning on the reliever is not treatment, it is the dashboard light telling you the controller plan is failing.

And the light is well calibrated. Going through three or more reliever canisters a year is tied, dose-dependently, to more flares and a higher risk of death, an association confirmed specifically in children. On top of that signal, the drug itself causes the jittery, racing-heart feeling at high doses. The honest summary is that frequent rescue use is the single most important number in this cabinet, and it points up the ladder, toward fixing the smolder, not toward keeping more reliever on hand.

⚠️ Heavy reliever use means review now, not more reliever

Needing the rescue inhaler more than the action plan allows, more than about two days a week outside of exercise, or burning through canisters, means the asthma is not controlled. Treat it as a prompt to have the controller plan reviewed without delay, because heavy short-acting reliever use is linked to more flares and higher mortality. It is a warning light, not a supply problem.

Nasal sprays: three different traps on one shelf

The nasal-spray shelf looks uniform and hides three completely different costs. Decongestant sprays (oxymetazoline, the "Afrin" type) cause rebound congestion (rhinitis medicamentosa, where the nose gets stuffier as the spray wears off, driving you to use more) within just a few days, which is why the rule is to limit them to about three days and no more. Intranasal steroid sprays are the genuinely useful long-term option, and their real local cost is occasional nosebleeds, more common with year-round use, while the widely feared "thinning of the lining" turns out to be a myth not supported by actual tissue studies, the fix is simply aiming the spray at the outer wall of the nostril, away from the septum. And antihistamine sprays dry the nose and can sedate. Same shelf, three different price tags, and the cheap-feeling decongestant is the one that quietly creates dependency.

Inhaled steroids: low exposure, not zero

The daily inhaled steroid is the controller everything else is built around, and its exposure is far lower than the oral bursts it prevents, mostly staying in the airway. Not zero, though: it carries a small, one-time effect on growth in children, on the order of a centimeter in final height, which is limited further by using the lowest effective dose, a spacer, and rinsing the mouth after. The honest framing is the one the medication-fears piece makes at length, this is the low-risk, high-value item in the cabinet, worth taking and worth monitoring, not worth fearing.

Oral steroids: the big one

The largest second price tag in the whole cabinet belongs to the oral steroid bursts, and it has its own full accounting in What Oral Steroids Actually Cost. The short version, and the through-line of this entire inventory, is that the bursts are where the cumulative harm concentrates, which is exactly why so much of this section is built to make them rare. So once a year, do what no single prescriber ever quite does: pull everything in the cabinet out and look at it as a set. Ask of each item not "does it work" but "what does it cost if my family takes it for years," and aim that question at the mechanisms, the anticholinergic burden, the reliever overuse, the rebound spray, rather than the brand names on the boxes. The medicines are doing real work. They just each carry a second price, and the family that can read the bill is the one that does not pay it blind.

References

Sources behind the claims in this piece. Listed at the bottom rather than inline so the prose reads cleanly. Each entry is what actually backs the claim it supports, not adjacent literature.

On antihistamines and anticholinergic burden:

On montelukast's neuropsychiatric effects, read honestly:

On reliever overuse as a marker of risk:

On the nasal-spray traps (rebound congestion, and the intranasal-steroid atrophy myth):

On the inhaled steroid as low-but-not-zero exposure:

The montelukast boxed warning itself is from the FDA prescribing label.

The tool that applies this. The member medication-risk deep dives weigh each asthma drug's second price tag, so you can read the tradeoff for your own child. → Member Library

Read next

Comments ()